Medigard selects site for trials
Thursday, 10 July, 2008
Medical device company Medigard [ASX; MGZ] will conduct clinical trials of its proprietary safety blood collection devices at Griffith University's Gold Coast campus.
The trials will be held at the university's Genomics Research Centre. 500 of the devices have been delivered to the centre for simulated clinical trials.
The trials are part of the company's FDA 510(k) application, a fast-tracking process for important, innovative or advanced medical devices.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
